These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24595521)

  • 21. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
    Simons WR; Jones D; Buzdar A
    Clin Ther; 2003 Nov; 25(11):2972-87. PubMed ID: 14693319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
    Thompson D; Taylor DC; Montoya EL; Winer EP; Jones SE; Weinstein MC
    Value Health; 2007; 10(5):367-76. PubMed ID: 17888101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
    Okubo I; Kondo M; Toi M; Ochiai T; Miki S
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):351-63. PubMed ID: 15791818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer Care Coordinators to Improve Tamoxifen Persistence in Breast Cancer: How Heterogeneity in Baseline Prognosis Impacts on Cost-Effectiveness.
    Nair N; Kvizhinadze G; Blakely T
    Value Health; 2016 Dec; 19(8):936-944. PubMed ID: 27987643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
    van Nuland M; Vreman RA; Ten Ham RMT; de Vries Schultink AHM; Rosing H; Schellens JHM; Beijnen JH; Hövels AM
    Breast Cancer Res Treat; 2018 Nov; 172(1):143-150. PubMed ID: 30006796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study.
    McCowan C; Wang S; Thompson AM; Makubate B; Petrie DJ
    Br J Cancer; 2013 Sep; 109(5):1172-80. PubMed ID: 23949153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Dranitsaris G; Verma S; Trudeau M
    Am J Clin Oncol; 2003 Jun; 26(3):289-96. PubMed ID: 12796603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
    Yang JJ; Park SK; Cho LY; Han W; Park B; Kim H; Lee KS; Hahn SK; Cho SI; Ahn SH; Noh DY;
    Clin Ther; 2010 Jun; 32(6):1122-38. PubMed ID: 20637966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term consequences of ovarian ablation for premenopausal breast cancer.
    Kwon JS; Pansegrau G; Nourmoussavi M; Hammond G; Carey MS
    Breast Cancer Res Treat; 2016 Jun; 157(3):565-73. PubMed ID: 27236562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk-benefit profiles of women using tamoxifen for chemoprevention.
    Nichols HB; DeRoo LA; Scharf DR; Sandler DP
    J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women.
    Smith TJ; Hillner BE
    J Clin Oncol; 2000 Jan; 18(2):284-6. PubMed ID: 10637241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
    Lux MP; Wöckel A; Benedict A; Buchholz S; Kreif N; Harbeck N; Kreienberg R; Kaufmann M; Beckmann MW; Jonat W; Hadji P; Distler W; Raab G; Tesch H; Weyers G; Possinger K; Schneeweiss A
    Onkologie; 2010; 33(4):155-66. PubMed ID: 20389141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
    Fisher B; Costantino JP; Wickerham DL; Redmond CK; Kavanah M; Cronin WM; Vogel V; Robidoux A; Dimitrov N; Atkins J; Daly M; Wieand S; Tan-Chiu E; Ford L; Wolmark N
    J Natl Cancer Inst; 1998 Sep; 90(18):1371-88. PubMed ID: 9747868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.